Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD

Respiratory Medicine

Volumn 105, Issue 4, 2011, Pages 571-579

  Worth, Heinrich ^a   Chung, Kian Fan ^b   Felser, James M ^c   Hu, Huilin ^c   Rueegg, Peter ^c  

^a KLINIKUM FÜRTH   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bronchodilators; Cardio cerebrovascular safety; Chronic obstructive pulmonary disease

Indexed keywords

FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; QT INTERVAL; SIDE EFFECT; STROKE; TREATMENT DURATION; VITAL SIGN;

ADULT; ALBUTEROL; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; MIDDLE AGED; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RISK FACTORS; SCOPOLAMINE DERIVATIVES; SMOKING;

EID: 79952280819     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.11.027     Document Type: Article

References (28)

1. 2-selective agonist. J Cardiovasc Electrophysiol 2004;15:316-22.
2. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253-60.
3. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring Jr E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70.
4. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: a study of the general population. COPD 2010;7:5-10.
5. 2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9.
6. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
7. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71.
8. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J; 2010;. doi:10.1183/09031936.00045810. published ahead of print.
9. Global initiative for chronic obstructive lung disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. Updated 2005. At: www.goldcopd.com [accessed 22.03.2010].
10. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994; 308:81-106. Erratum in: BMJ 1994;308:1540.
11. FDA. U.S. Food and Drug Administration. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005 Available at: http://www.fda.gov/ RegulatoryInformation/Guidances/ucm129335.htm [accessed 22.03.10]
12. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007;81:108-13. (Pubitemid 46050875)
13. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009;4:337-49.
14. Khindri S, Sabo R, Harris S, Jennings S, Drollmann AF. A thorough QT study on the effect of indacaterol on cardiac safety in healthy subjects. Am J Respir Crit Care Med 2009;179:A2463 [abstract].
15. Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005;127:2057-63.
16. 2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008;87:319-28.
17. Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv RespirDis 2008;2:37-48. (Pubitemid 351472129)
18. Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, doubleblind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29:2167-78. Erratum in: Clin Ther 2009;31:920.
19. Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, et al. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2007;20:571-9. (Pubitemid 47082477)
20. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and metaanalysis. JAMA 2008;300:1439-50. Erratum in: JAMA 2009;301:1227-30.
21. FDA. U.S. Food and Drug Administration. Follow-up to the October 2008 updated early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). At: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm197429.htm. [accessed 22.03.10].
22. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
23. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.
24. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55.
25. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103:1421-9.
26. Lee TA, Pickard S, Au DH, Bartle B, Weiss KB. Risk of death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Int Med 2008;149:380-90.
27. Wood-Baker R, Cochrane B, Naughton MT. Cardiovascular mortality and morbidity in COPD: the impact of bronchodilator treatment. Intern Med J 2010;40:94-101.
28. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010;65:719-25.